- Home
- SATL vs EYPT Comparison
SATL vs EYPT Comparison
Compare SATL & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SATL
- EYPT
- Stock Information
- Founded
- SATL 2010
- EYPT 1987
- Country
- SATL Uruguay
- EYPT United States
- Employees
- SATL N/A
- EYPT N/A
- Industry
- SATL Radio And Television Broadcasting And Communications Equipment
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- SATL Technology
- EYPT Industrials
- Exchange
- SATL Nasdaq
- EYPT Nasdaq
- Market Cap
- SATL 379.7M
- EYPT 427.9M
- IPO Year
- SATL N/A
- EYPT 2005
- Fundamental
- Price
- SATL $3.59
- EYPT $5.06
- Analyst Decision
- SATL
- EYPT Strong Buy
- Analyst Count
- SATL 0
- EYPT 8
- Target Price
- SATL N/A
- EYPT $25.71
- AVG Volume (30 Days)
- SATL 822.6K
- EYPT 726.5K
- Earning Date
- SATL 04-14-2025
- EYPT 03-05-2025
- Dividend Yield
- SATL N/A
- EYPT N/A
- EPS Growth
- SATL N/A
- EYPT N/A
- EPS
- SATL N/A
- EYPT N/A
- Revenue
- SATL $12,870,000.00
- EYPT $43,273,000.00
- Revenue This Year
- SATL N/A
- EYPT N/A
- Revenue Next Year
- SATL N/A
- EYPT N/A
- P/E Ratio
- SATL N/A
- EYPT N/A
- Revenue Growth
- SATL 27.75
- EYPT N/A
- 52 Week Low
- SATL $0.72
- EYPT $5.00
- 52 Week High
- SATL $5.49
- EYPT $23.65
- Technical
- Relative Strength Index (RSI)
- SATL 49.62
- EYPT 32.55
- Support Level
- SATL $3.63
- EYPT $5.87
- Resistance Level
- SATL $4.34
- EYPT $6.69
- Average True Range (ATR)
- SATL 0.38
- EYPT 0.43
- MACD
- SATL -0.02
- EYPT -0.08
- Stochastic Oscillator
- SATL 35.90
- EYPT 3.52
About SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.